Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record.

Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features

Open access
Raizer, Jeffrey J., Hwu, Wen-Jen, Panageas, Katherine S., Wilton, Andrew, Baldwin, Drew E., Bailey, Elizabeth, von Althann, Caroline, Lamb, Lynne A., Alvarado, Gladys, Bilsky, Mark H., Gutin, Philip H. · 2008 · Neuro-Oncology

Abstract

Brain metastases (BM) are among the most devastating and debilitating complications of melanoma. This retrospective study was conducted to gain a better understanding of patient and disease characteristics that have the greatest impact on overall survival in melanoma patients with BM; therapeutic interventions were also assessed. The records of all patients diagnosed with cutaneous melanoma and BM who were seen at Memorial Sloan-Kettering Cancer Center between 1991 and 2001 were retrospectively reviewed. A variety of factors, including age at diagnosis of stage IV disease, gender, race, disease stage at diagnosis, presence of BM at diagnosis of stage IV disease, neurologic symptoms, radiographic findings, number of BM, status and site(s) of extracranial metastasis, and treatment modalities, were analyzed for correlation with overall survival using univariate and multivariate Cox regression models. The records of 355 patients with BM were included in the analysis. On univariate analysis, seven patient and disease characteristics were significantly associated with poorer survival: age > 65 years, extracranial metastases, BM at stage IV diagnosis, neurologic symptoms, four or more BM, hydrocephalus, and leptomeningeal metastases. Of these, age, extracranial metastasis, neurologic symptoms, and number of BM were significantly associated with poorer survival in a multivariate analysis. Multivariate analysis of treatment modalities suggested that patients who had surgery, radiosurgery, or chemotherapy with temozolomide had improved survival outcomes, although this analysis has limitations. The prognostic factors identified in this retrospective study should be considered when making treatment decisions for patients with BM and used as stratification factors in future clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1215/15228517-2007-058

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 230

Metadata

Authors
Raizer, J. J., Hwu, W.-J., Panageas, K. S., Wilton, A., Baldwin, D. E., Bailey, E., von Althann, C., Lamb, L. A., Alvarado, G., Bilsky, M. H., & Gutin, P. H.
Venue
Neuro-Oncology
Published
2008-04-01
Volume
10
Issue
2
Pages
199-207
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2133857293
Cited by
230
References
0
FWCI
4.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. https://app.cochat.ai/papers/10.1215/15228517-2007-058
The paper
Raizer, J. J., Hwu, W.-J., Panageas, K. S., Wilton, A., Baldwin, D. E., Bailey, E., von Althann, C., Lamb, L. A., Alvarado, G., Bilsky, M. H., & Gutin, P. H. (2008). Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro-Oncology. https://doi.org/10.1215/15228517-2007-058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.